There's a difference between a short-term trader and a trend follower.
A trend follower doesn't necessarily do fundamental analysis, but may be in a stock for a very long time.
For most of my stocks, I don't really care much what the company does but focus on the charts. Also look at revenue growth, earnings growth, that might lead to big moves.
Biotech is different in my book, because the binary events can cause crazy, sometimes unpredictable swings.
But with AMRN, since Reduce-it results especially, I have been convinced price success is a matter of time.
O'Neil's book "how to make money in stocks" is a key book. He outlines many principles. Among them, overall market have key effect on most stocks. Charts are a picture of supply and demand. A company needs to be experiencing growth for stock to move.
Another is "The Way of the Turtle: the secret methods that turned ordinary individuals into legendary traders"
My opinion is that these methods are useful tools, but investing/trading/speculating is a complicated business.
I bought and sold some AMRN back in 2010-2011 timeframe.
Although I believed the drug worked at the time, I didn't know in as much detail how great it was. Despite the potential of the drug, the FDA didn't open their door to success. If I had known more, maybe I wouldn't have sold but I would have been more frustrated.
As someone who likes to pick stocks, at some point one has to know when holding a company with a great product is unproductive. Some great products are in companies wiht poor management. Or subject to forces outside their control.
In the time since I sold AMRN in 2011, I've had some big winners in JAZZ, BABA, EXAS, ADBE, others. Certainly taken some losses also.
Kinda has AMRN on my radar and bought a small amount in 2018, loaded up after REDUCE-IT.
Since then, I believe it's the surest thing in the market and I'll hold a big position in it until its bought or I think it's overvalued.
